Financing the efficient delivery of medical services while reducing costs for consumers as well as health care providers is among the most challenging domestic policy problems many countries face. RAND addresses health economics issues through innovative, high-profile research in an effort to improve the efficiency of health care organizations, reduce costs for providers and consumers, and improve financing in health care markets.
In its second term, the Obama Administration can restrain further health care spending growth—without compromising quality—by employing four broad strategies: fostering efficient and accountable providers, engaging and empowering consumers, promoting population health, and facilitating high-value innovation.
Evaluates factors that affect the financial performance of hospice.
Advocates of high-deductible health plans, which shift more of the cost of care to individuals, believe that consumers will more carefully assess the balance of health care benefits versus costs, ultimately improving efficiency and quality of care.
In this paper the authors examine the incremental cost of marijuana comorbidity for alcohol, mood and thought diagnoses in hospital settings.
Uses data from California to compare actual prices paid by uninsured patients with prices paid by commercial and Medicare patients. Uninsured patients pay prices similar to those of Medicare patients, and hospital prices to the uninsured have risen.
Data from the Employment Cost Index show that health insurance costs relative to payroll increased 34 percent between 1996 and 2005 and that the increase was largest for businesses paying low wages; simultaneously, data from the Employee Benefits Survey show that benefit packages became less generous, yet cost growth was not paralleled by a commensurate decrease in employer offers.
Examines the discipline of health services research. Often loosely referred to as outcomes research, it is primarily focused on the study of access to care, costs of care, and quality of care.
Medicare beneficiaries who died while enrolled in independent practice association model HMOs, including the Kaiser model, had many fewer hospital days during the two years before death than beneficiaries who died with fee-for-service coverage.
Despite the enormous and ongoing increase in health care expenditures, patients receive only half of recommended care, and many receive care that is equivocal or harmful. Ideas to improve quality are examined.
Examines financial implications of the Centers for Medicare & Medicaid Services Hierarchical Condition Categories risk-adjustment model on Medicare payments for individuals with comorbid chronic conditions. Some payments were underpredicted.
To assess the evidence for the effect of disease management on quality of care, disease control, and cost, with a focus on populationbased programs.
Some states use physicians' histories of medical malpractice payments to try to reduce the incidence of medical malpractice (and for other reasons).
Although the data presented in this chapter focus on the direct medical costs of Interstitial cystitis (IC), patients are equally, if not more, affected by loss of work opportunities, effects on relationships, and overall diminished quality of life.
Kidney cancer, the third most common urologic malignancy and the seventh most common cancer overall, was diagnosed in an estimated 35,000 Americans in 2005, and nearly 13,000 died from it.
The economic impact of inpatient treatment for pediatric vesicoureteral reflux is considerable.
The burden of disease due to erectile dysfunction in the United States will increase with the aging of the male population.
The costs of treating bladder cancer increased steadily during a 6-year period despite a decrease in inpatient care.
Clinicians find it difficult to know which drugs are covered for their Medicare patients because formularies vary widely among Medicare Part D plans
Infertile males generally seek infertility care outside of traditional reimbursement patterns.
Increasing trends in the incidence of and costs associated with kidney cancer have been apparent for more than 10 years.
Spending in the US for the diagnosis and management of prostatitis, exclusive of pharmaceutical spending, appears to be increasing with time.